series-c-plus
Stage
7
Investors
About
Mineralys Therapeutics develops therapies targeting aldosterone dysregulation to improve outcomes in patients with hypertension, chronic kidney disease (CKD), and related cardio-renal-metabolic disorders.
Explore Mineralys Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.